Alogliptin - effektivnyy i bezopasnyy ingibitor dipeptidilpeptidazy-4 v terapii bol'nykh sakharnym diabetom 2 tipa
- Authors: Mkrtumyan A.M1
-
Affiliations:
- Issue: No 5 (2015)
- Pages: 20-27
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287807
- ID: 287807
Cite item
Open Access
Access granted
Abstract
Alogliptin is new dipeptidyl peptidase-4 (DPP-4) inhibitor, which has a high affinity and high specificity for this enzyme, thereby provides rapid and sustained inhibition of DPP-4 with a significant reduction of postprandial plasma glucose concentrations in patients with type 2 diabetes mellitus (DM2). Efficacy and safety of alogliptin were studied in five III phase placebo-controlled studiesnusing doses of 12.5 and 25 mg once a day. The drug was evaluated as monotherapy and in combination with sulfonylurea, metformin, pioglitazone, metformin±sulfonylurea, insulin±metformin. Results of studies indicate that alogliptin seems effective therapeutic option for DM2 both as monotherapy and in combination with antidiabetic drugs of other classes. It is emphasized that alogliptin in addition to high efficiency in clinical trials also has demonstrated high safety, including cardiovascular safety.
Full Text
References
- IDF Diabetes Atlas. 6-th edition. 2013.
- Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-705.
- Capuano A., Sportiello L., Maiorino M.I., Rossi F., Giugliano D., Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy -focus on alogliptin. Drug Des. Devel. Ther. 2013;7:989-1001.
- Feng J., Zhang Z., Wallace M.B., Stafford J.A., Kaldor S.W., Kassel D.B., Navre M., Shi L., Skene R.J., Asakawa T., Takeuchi K., Xu R., Webb D.R., Gwaltney S.L. 2nd. Discovery of alogliptin: a potent, selective, bioavail-able, and efficacious inhibitor of dipepti-dyl peptidase IV. J. Med. Chem. 2007;50: 2297-300.
- Covington P., Christopher R., Davenport M., Fleck P., Mekki Q.A., Wann E.R., Karim A. Pharmacokinetic, pharmacodynamic, and tol-erability profiles of the dipeptidyl peptidase 4 inhibitor alogliptin: a randomized, doubleblind, placebo-controlled multiple-dose study in adult patients with type 2 diabetes. Clin. Ther. 2008;30:499-512.
- Defronzo R.A., Fleck P.R., Wilson C.A., Mekki Q.; on behalf of the Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes mellitus and inadequate gly-cemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31:2315-7.
- Nauck M.A., Ellis G.C., Fleck P.R., Wilson C.A., Mekki Q. for the Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int. J. Clin. Pract. 2009;63:46-55.0
- Pratley R.E., Reusch J.E., Fleck P.R., Wilson C.A., Mekki Q.; Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled study. Curr. Med. Res. Opin. 2009;25( 10):2361-71.
- Yalt J.-F. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J. Am. Soc. Nephrol. 2005;16:S7-10.
- Pratley R.E., Kipnes M.S., Fleck P.R., Wilson C., Mekki Q. on behalf of the Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes. Metab. 2009;11:167-76.
- Rosenstock J., Rendell M.S., Gross J.L. Fleck P.R., Wilson C.A., Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA( 1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes. Metab. 2009; 11(12): 1145-52.
Supplementary files
